Document Detail


Correction of hemodialysis anemia is associated with significant increase in serum concentration of IGF-I in patients treated with erythropoietin: a randomized controlled study.
MedLine Citation:
PMID:  16132779     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The effect of erythropoietin (EPO) therapy on the serum level of IGF-I among hemodialysis patients is debated. The aim of this study is to study the effect of EPO on the erythropoiesis and the change of serum level of IGF-I among adequately hemodialyzed patients. PATIENTS AND METHODS: Forty patients (25 males and 15 females) who had an adequate level of both hemodialysis and nutrition were randomly allocated into two equal groups. Besides parenteral iron, the first group of patients received a conventional EPO dose regimen of 2000 U subcutaneously (SC) thrice weekly, the second group of patients remained on parenteral iron and ranked as a control group. The patients were subjected to thorough laboratory investigations. IGF-I concentration was measured before and at the end of the study. RESULTS: Both groups were comparable in their demographic, laboratory, dialysis level, and nutritional status. There was no statistical differences in hemoglobin, hematocrit %, iron store indices and serum level of IGF-I at the study entry. We found a significant rise of both hemoglobin and hematocrit as well as IGF-I serum level in the EPO group at the end of the study in comparison to their values at the starting points in comparison to the control group (P< 0.001). CONCLUSION: Erythropoietin therapy enhances erythropoiesis and modulates the serum concentration of IGF-I.
Authors:
Hussein A Sheashaa; Abdalla Khalil; Mohammed M El Aarman; Fagr B El-Shahat; Amal Selim; Soma Sherif Abd El-Gawad
Related Documents :
25370319 - Low vitamin d status is associated with increased titers of thyroid stimulating hormone...
19954849 - Pop levels in breast milk and maternal serum and thyroid hormone levels in mother-child...
12145459 - Red cell mass, spleen size and plasma erythropoietin in polycythaemia vera and apparent...
1601509 - Effect of subcutaneous administration of recombinant human erythropoietin on plasma pro...
2139159 - Influence of erythropoietin treatment on plasma renin activity, aldosterone, vasopressi...
9112059 - Relationship between erythrocyte-to-plasma distribution ratio of cyclosporin and lympho...
21274319 - Vitamin d deficiency rickets mimicking pseudohypoparathyroidism.
19855329 - Neuromuscular performance of elite rugby union players and relationships with salivary ...
399939 - Racial differences in pressure, volume and renin interrelationships in essential hypert...
Publication Detail:
Type:  Case Reports; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  International urology and nephrology     Volume:  37     ISSN:  0301-1623     ISO Abbreviation:  Int Urol Nephrol     Publication Date:  2005  
Date Detail:
Created Date:  2005-08-31     Completed Date:  2006-09-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0262521     Medline TA:  Int Urol Nephrol     Country:  Hungary    
Other Details:
Languages:  eng     Pagination:  153-8     Citation Subset:  IM    
Affiliation:
Nephrology Unit, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. drhattia@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anemia / blood*,  drug therapy*,  etiology
Erythropoiesis / drug effects
Erythropoietin / pharmacology,  therapeutic use*
Female
Hematocrit
Humans
Insulin-Like Growth Factor I / analysis*
Male
Middle Aged
Renal Dialysis / adverse effects*
Chemical
Reg. No./Substance:
11096-26-7/Erythropoietin; 67763-96-6/Insulin-Like Growth Factor I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pregnancy in peritoneal dialysis: a case report and review of adequacy and outcomes.
Next Document:  Self-assessed sleep quality in chronic kidney disease.